Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nintedanib

- PMLiVE

NHS England proposes handing CDF remit to NICE

Comes after a difficult two years for the silo budget

- PMLiVE

EFPIA’s Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

Boehringer Ingelheim headquarters

Boehringer plans new filings for Giotrif in lung cancer

Firm to file drug for squamous cell carcinoma of the lung

- PMLiVE

Boehringer’s ASCO blog picks up digital excellence award

Work by Ogilvy HealthPRwins Prescription Products/Patient Health prize

- PMLiVE

Boehringer’s Spiriva combo approved in first EU markets

Combination therapy available countries including the UK, Ireland and Spain

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

- PMLiVE

Just manufacturing pills ‘no longer good enough for patients’

Pharma must truly move beyond the pill and embrace digital health, according to industry heads

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Boehringer Ingelheim headquarters

NICE U-Turn on Boehringer oncology drug

England’s drug price watchdog now recommends Vargatef for lung cancer after price cut

- PMLiVE

Boehringer launches iPhone app for patients on Gilotrif

App offers treatment guide for those taking its cancer drug

Boehringer Ingelheim headquarters

Boehringer bags FDA approval for Spiriva-based combo

Stiolto given the thumbs up as a once-daily maintenance therapy for COPD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links